Registration was successful!
Please follow the link from the email sent to

Russia’s EpiVacCorona Coronavirus Vaccine Approved for Citizens Over 60

© Sputnik / Grigory Sysoev / Go to the photo bankA view shows packages of Russian coronavirus vaccine EpiVacCorona, developed by the Vektor State Research Center of Virology and Biotechnology, at the production unit Vector-BiAlgam, in Novosibirsk, Russia
A view shows packages of Russian coronavirus vaccine EpiVacCorona, developed by the Vektor State Research Center of Virology and Biotechnology, at the production unit Vector-BiAlgam, in Novosibirsk, Russia - Sputnik International, 1920, 05.03.2021
Subscribe
The vaccine, developed by the Vector State Research Centre of Virology and Biotechnology, has been earlier proven to provide a year of protection against COVID-19.

Russia’s EpiVacCorona vaccine has been authorised for seniors aged 60 and over, the national consumer rights protection watchdog, Rospotrebnadzor, announced on Friday.

"As a result of studies that have confirmed vaccine immunogenicity and safety for senior patients, the EpiVacCorona vaccine has been approved for use in people over 60 years of age," Rospotrebnadzor said in a statement.

The vaccine is a peptide-based drug that relies on a synthetic platform. Artificially-synthesised short fragments of viral proteins - peptides, which are contained in the vaccine, help the immune system learn how to recognise and then neutralise the virus.

The Russian authorities announced earlier this month that the country has already produced 80,000 doses of EpiVacCorona.

During the coronavirus pandemic, Russia has taken the lead in the race to develop a vaccine, creating three different jabs: Sputnik V, developed by Moscow’s Gamaleya Institute; EpiVacCorona by the Siberian research centre Vector; and the Chumakov Research Institute's CoviVac.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала